SERA Projected Dividend Yield
Cl A/Sera Prognostics Inc ( NASDAQ : SERA )Sera Prognostics is a women's health company. Co.'s primary commercial product, the PreTRM test, is a commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during week 18 or 20 of gestation that provides a prediction of the expectant mother's risk of delivering spontaneously before 37 weeks' gestation. Co. is discovering and developing several additional biomarker tests to predict other conditions of pregnancy, such as preeclampsia, and gestational diabetes, among others. 20 YEAR PERFORMANCE RESULTS |
SERA Dividend History Detail SERA Dividend News SERA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |